Rapid recovery from panobinostat (LBH589)-induced thrombocytopenia in mice involves a rebound effect of bone marrow megakaryocytes

Leukemia

Volumn 25, Issue 2, 2011, Pages 362-365

  Giver, C R ^a,b   Jaye, D L ^c   Waller, E K ^a,b   Kaufman, J L ^a,b   Lonial, S ^a,b  

^a Department of Hematology and Medical Oncology ^*  (United States)

^b EMORY UNIVERSITY   (United States)

^c EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FIBRINOGEN RECEPTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PANOBINOSTAT; THROMBOPOIETIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG HALF LIFE; FEMALE; LETTER; MEGAKARYOCYTE; MOUSE; NONHUMAN; PRIORITY JOURNAL; REBOUND; SIGNAL TRANSDUCTION; T CELL LYMPHOMA; THROMBOCYTE COUNT; THROMBOCYTOPENIA; THROMBOCYTOPOIESIS; TREATMENT RESPONSE;

EID: 79751534825     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2010.262     Document Type: Letter

References (12)

1. Kenney B, Stack G. Drug-induced thrombocytopenia. Arch Pathol Lab Med 2009; 133: 309-314.
2. Lonial S, Waller EK, Richardson PG, Jagannath S, Orlowski RZ, Giver CR et al. Risk factors and kinetics of thrombocytopenia associated with bortezomib for relapsed, refractory multiple myeloma. Blood 2005; 106: 3777-3784. (Pubitemid 41739012)
3. Rasheed W, Bishton M, Johnstone RW, Prince HM. Histone deacetylase inhibitors in lymphoma and solid malignancies. Expert Rev Anticancer Ther 2008; 8: 413-432. (Pubitemid 351836289)
4. Catley L, Weisberg E, Kiziltepe T, Tai YT, Hideshima T, Neri P et al. Aggresome induction by proteasome inhibitor bortezomib and alpha-tubulin hyperacetylation by tubulin deacetylase (TDAC) inhibitor LBH589 are synergistic in myeloma cells. Blood 2006; 108: 3441-3449.
5. Ellis L, Pan Y, Smyth GK, George DJ, McCormack C, Williams-Truax R et al. Histone deacetylase inhibitor panobinostat induces clinical responses with associated alterations in gene expression profiles in cutaneous T-cell lymphoma. Clin Cancer Res 2008; 14: 4500-4510.
6. Nishioka C, Ikezoe T, Yang J, Komatsu N, Bandobashi K, Taniguchi A et al. Histone deacetylase inhibitors induce growth arrest and apoptosis of HTLV-1-infected T-cells via blockade of signaling by nuclear factor kappaB. Leuk Res 2008; 32: 287-296. (Pubitemid 351215535)
7. Hideshima T, Chauhan D, Richardson P, Mitsiades C, Mitsiades N, Hayashi T et al. NF-kappa B as a therapeutic target in multiple myeloma. J Biol Chem 2002; 277: 16639-16647. (Pubitemid 34967682)
8. Zhang Y, Sun S, Wang Z, Thompson A, Kaluzhny Y, Zimmet J et al. Signaling by the Mpl receptor involves IKK and NF-kappaB. J Cell Biochem 2002; 85: 523-535. (Pubitemid 34465132)
9. Mason KD, Carpinelli MR, Fletcher JI, Collinge JE, Hilton AA, Ellis S et al. Programmed anuclear cell death delimits platelet life span. Cell 2007; 128: 1173-1186. (Pubitemid 46427871)
10. Fielder PJ, Gurney AL, Stefanich E, Marian M, Moore MW, Carver-Moore K et al. Regulation of thrombopoietin levels by c-mpl-mediated binding to platelets. Blood 1996; 87: 2154-2161.
11. Corash L, Levin J, Mok Y, Baker G, McDowell J. Measurement of megakaryocyte frequency and ploidy distribution in unfractionated murine bone marrow. Exp Hematol 1989; 17: 278-286. (Pubitemid 19073864)
12. Matsuoka H, Unami A, Fujimura T, Noto T, Takata Y, Yoshizawa K et al. Mechanisms of HDAC inhibitor-induced thrombocytopenia. Eur J Pharmacol 2007; 571(2-3): 88-96. (Pubitemid 47379689)